Navigation Links
Xenon Announces Appointment of EVP, Research & Development
Date:5/17/2010

VANCOUVER, May 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce today that it has appointed Tarek S. Mansour as Executive Vice President, Research and Development.

"We are delighted to welcome Tarek to the Xenon team," commented Simon Pimstone, Xenon's President and CEO. "Tarek is a world-class R&D executive whose experience in discovering products, a number of which are now on the market, will further enhance Xenon's capabilities.  Tarek has had the unique experience of holding senior leadership positions within both biotech and more traditional pharmaceutical companies.  His successful careers at Biochem Pharma and Wyeth Pharmaceuticals (now Pfizer) have armed Tarek with best-in-class drug discovery and development practice and we are confident that Tarek will make a major contribution to Xenon's future innovative R&D efforts."

Dr. Mansour has spent nearly 25 years in the life sciences industry with positions at Biochem Pharma, and Wyeth Pharmaceuticals (now Pfizer). His most recent position at Wyeth Research was as VP, Chemical Sciences Head over multiple research sites. Dr. Mansour received his PhD in Chemistry from the University of Missouri - Columbia.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  Xenon has multiple products in phase 1 and 2 clinical development.  For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Biologic Products Announces First Quarter 2010 Results
2. Dehaier Medical Systems Announces First Quarter Net Income Up 54%
3. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
4. Still River Systems Announces Production Milestone for the Worlds Smallest High-Energy Proton Therapy Accelerator
5. joimax(R) Holds the First International TESSYS(R) User Meeting in Veenhuizen, The Netherlands, and Announces the Launch of Various New Products for Endoscopic Spinal Surgery
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
8. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
9. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
10. Cogdell Spencer Announces Commencement of Common Stock Offering
11. Mylan Announces Upsizing and Pricing of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... NEW YORK , Jan. 23, 2017 /PRNewswire/ ... a long way from conventional syringes with vials ... free systems. These modern devices have become preferred ... demand for prefilled syringes has been rising strongly ... of healthcare facilities are now adopting this format ...
(Date:1/24/2017)... , January 23, 2017 ... Growth A majority of medicines ... formulating Active Pharmaceutical Ingredients (API), and such processes require ... glycol. Production of pharmaceutical solvents continues to ... excluding Japan (APEJ) region as ...
(Date:1/23/2017)... Endo International plc (NASDAQ / TSX: ENDP) ... a joint motion in the U.S. District Court for ... seeking the entry of a ten-year Stipulated Order for ... the FTC and Endo relating to the patent infringement ... ER and Lidoderm® products.  It also resolves the FTC,s ...
Breaking Medicine Technology:
(Date:1/24/2017)... Scottsdale, AZ (PRWEB) , ... January 24, 2017 , ... ... than 30 lives in the last month. Yellow fever is primarily spread through contact ... the health community’s focus on how to prevent its spread. , According to multiple ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Spiritual ... improve the connection with God. “Spiritual Vitamins: A Spiritual Energy Booster” is the ... Christian Faith Publishing, Mathai Yohannan’s new book engages the mind and spirit in ...
(Date:1/24/2017)... ... January 23, 2017 , ... CLICKco LLC, a ... drink, announced its CLICK® Coffee Protein Drink is now available for purchase on ... has become popular among health-conscious consumers who love coffee but are looking to ...
(Date:1/24/2017)... ... 23, 2017 , ... Texas Home Health, an AccentCare, Inc. ... care service companies: Padre Home Health in Corpus Christi, Texas, and Royalty Personal ... regarded in their respective markets, these two agencies align with Texas Home Health’s ...
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania addiction treatment ... Alpine Springs Rehabilitation & Recovery Center’s new website can be found at ... its redesigned and retooled website. The treatment center has also revamped its social ...
Breaking Medicine News(10 mins):